|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0008976,
umls-concept:C0034656,
umls-concept:C0205390,
umls-concept:C0995188,
umls-concept:C1335703,
umls-concept:C1512162,
umls-concept:C1513186,
umls-concept:C1696465,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
34
|
|
pubmed:dateCreated |
2005-11-29
|
|
pubmed:abstractText |
Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months. These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8646-54
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16314626-Adult,
pubmed-meshheading:16314626-Aged,
pubmed-meshheading:16314626-Aged, 80 and over,
pubmed-meshheading:16314626-Antibodies, Monoclonal,
pubmed-meshheading:16314626-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16314626-Carcinoma, Squamous Cell,
pubmed-meshheading:16314626-Cisplatin,
pubmed-meshheading:16314626-Cross-Over Studies,
pubmed-meshheading:16314626-Dose-Response Relationship, Drug,
pubmed-meshheading:16314626-Drug Hypersensitivity,
pubmed-meshheading:16314626-Female,
pubmed-meshheading:16314626-Follow-Up Studies,
pubmed-meshheading:16314626-Head and Neck Neoplasms,
pubmed-meshheading:16314626-Hematologic Diseases,
pubmed-meshheading:16314626-Humans,
pubmed-meshheading:16314626-Immunohistochemistry,
pubmed-meshheading:16314626-Male,
pubmed-meshheading:16314626-Middle Aged,
pubmed-meshheading:16314626-Neoplasm Metastasis,
pubmed-meshheading:16314626-Neoplasm Recurrence, Local,
pubmed-meshheading:16314626-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16314626-Severity of Illness Index,
pubmed-meshheading:16314626-Skin Diseases,
pubmed-meshheading:16314626-Survival Analysis,
pubmed-meshheading:16314626-Time Factors,
pubmed-meshheading:16314626-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
|
|
pubmed:affiliation |
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. barbara.burtness@fccc.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
